Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022, with a specific reporting date of February 9, 2022. The document serves as a transaction notification regarding insider trading activities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to reporting a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADSs) |
| Instrument ISIN | US37733W1053 |
| Transaction Date | February 7, 2022 |
| Transaction Venue | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details two separate acquisitions of GSK ADSs by Dr. H. Barron, Chief Scientific Officer and President, R&D, on February 7, 2022:
- Executive Supplemental Savings Plan: Acquisition of 1,041.653 ADSs at $44.9900 per share.
- 401(k) Plan: Acquisition of 187 ADSs at $44.9900 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is a regulatory disclosure of a routine executive compensation-related transaction.
Investor Verification Checklist
- Verify the total number of ADSs held by Dr. H. Barron following these transactions.
- Confirm the pricing of $44.9900 aligns with the market price of GSK ADSs on February 7, 2022.
- Review the company's annual Form 20-F for comprehensive financial performance data, as this Form 6-K does not contain such information.